Christopher Di Simone

1.0k total citations · 1 hit paper
10 papers, 591 citations indexed

About

Christopher Di Simone is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Christopher Di Simone has authored 10 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in Christopher Di Simone's work include Virus-based gene therapy research (3 papers), Renal cell carcinoma treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Christopher Di Simone is often cited by papers focused on Virus-based gene therapy research (3 papers), Renal cell carcinoma treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Christopher Di Simone collaborates with scholars based in United States, United Kingdom and Spain. Christopher Di Simone's co-authors include Michael J. Buchmeier, Michelle Zandonatti, Emmett V. Schmidt, Allen Lee Cohn, Vicky Makker, Perminder S. Sachdev, David M. Hyman, Drew Rasco, Matthew H. Taylor and Matthew Guo and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

Christopher Di Simone

10 papers receiving 588 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 360 citations Vicky Makker, Drew Rasco et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Di Simone United States	7	274	135	114	113	107	10	591
Brigitte A. Barrette United States	9	277 1.0×	62 0.5×	143 1.3×	66 0.6×	86 0.8×	12	734
Chih‐Chien Cheng Taiwan	8	114 0.4×	59 0.4×	126 1.1×	143 1.3×	88 0.8×	24	565
Ben X. Wang Canada	9	190 0.7×	98 0.7×	128 1.1×	246 2.2×	53 0.5×	33	511
Ryuichi Nakashima Japan	13	135 0.5×	74 0.5×	212 1.9×	32 0.3×	45 0.4×	18	606
Bergerat Jp France	14	125 0.5×	50 0.4×	136 1.2×	140 1.2×	81 0.8×	42	536
Takuma Miura Japan	12	111 0.4×	71 0.5×	57 0.5×	49 0.4×	58 0.5×	42	441
Qiong-Lan Tang China	11	119 0.4×	34 0.3×	186 1.6×	62 0.5×	40 0.4×	30	431
Christine‐Ivy Liacos Greece	12	91 0.3×	149 1.1×	178 1.6×	111 1.0×	39 0.4×	33	509
Hayato Yamauchi Japan	12	173 0.6×	72 0.5×	83 0.7×	89 0.8×	36 0.3×	41	427
Kate Poropatich United States	12	156 0.6×	112 0.8×	125 1.1×	170 1.5×	156 1.5×	17	601

Countries citing papers authored by Christopher Di Simone

Since Specialization

Citations

This map shows the geographic impact of Christopher Di Simone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Di Simone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Di Simone more than expected).

Fields of papers citing papers by Christopher Di Simone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Di Simone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Di Simone. The network helps show where Christopher Di Simone may publish in the future.

Co-authorship network of co-authors of Christopher Di Simone

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Di Simone. A scholar is included among the top collaborators of Christopher Di Simone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Di Simone. Christopher Di Simone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2024). Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. Journal for ImmunoTherapy of Cancer. 12(1). e007929–e007929. 5 indexed citations

Lee, Chung‐Han, Amishi Y. Shah, James J. Hsieh, et al.. (2020). Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology. 38(15_suppl). 5008–5008. 31 indexed citations

Lee, Chi‐Hang, Amishi Y. Shah, James J. Hsieh, et al.. (2020). 710P Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses. Annals of Oncology. 31. S558–S559. 3 indexed citations

McDermott, David F., Jae‐Lyun Lee, Georg A. Bjarnason, et al.. (2020). First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.. Journal of Clinical Oncology. 38(15_suppl). 5069–5069. 7 indexed citations

Witzig, Thomas E., Kami J. Maddocks, Sven de Vos, et al.. (2019). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 37(15_suppl). 7519–7519. 12 indexed citations

Makker, Vicky, Drew Rasco, Nicholas J. Vogelzang, et al.. (2019). Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology. 20(5). 711–718. 360 indexed citations breakdown →

Witzig, T.E., Kami J. Maddocks, Sven de Vos, et al.. (2019). ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. Hematological Oncology. 37(S2). 327–328. 6 indexed citations

Simone, Christopher Di & Michael J. Buchmeier. (1995). Kinetics and pH Dependence of Acid-Induced Structural Changes in the Lymphocytic Choriomeningitis Virus Glycoprotein Complex. Virology. 209(1). 3–9. 60 indexed citations

Simone, Christopher Di, Michelle Zandonatti, & Michael J. Buchmeier. (1994). Acidic pH Triggers LCMV Membrane Fusion Activity and Conformational Change in the Glycoprotein Spike. Virology. 198(2). 455–465. 100 indexed citations

10.

Simone, Christopher Di & John D. Baldeschwieler. (1992). Membrane fusion of mumps virus with ghost erythrocytes and CV-1 cells. Virology. 191(1). 338–345. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact